These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 922357)
1. Post-marketing surveillance of adverse reactions to new medicines. Wilson AB Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357 [No Abstract] [Full Text] [Related]
3. New strategies for drug monitoring. Br Med J; 1977 Apr; 1(6065):861-2. PubMed ID: 851762 [No Abstract] [Full Text] [Related]
4. Control and distribution of medicines in the future. Cook AM R Soc Health J; 1971; 91(5):222-4. PubMed ID: 5154143 [No Abstract] [Full Text] [Related]
6. Post-marketing surveillance in the UK (1984). Lawson DH Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035 [No Abstract] [Full Text] [Related]
7. Monitoring of drugs after marketing. J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114 [No Abstract] [Full Text] [Related]
8. The safety of new drugs. Hull CJ Br J Anaesth; 1989 Jun; 62(6):587-9. PubMed ID: 2751914 [No Abstract] [Full Text] [Related]
9. Post-marketing surveillance of licensed medicinal and other products. Griffin JP Health Bull (Edinb); 1981 Nov; 39(6):356-66. PubMed ID: 7035401 [No Abstract] [Full Text] [Related]
10. European Medicines Agency assesses safety reporting at Roche. Marshall H Lancet Oncol; 2012 Aug; 13(8):e331. PubMed ID: 23024993 [No Abstract] [Full Text] [Related]
11. [International efforts in the field of drug safety]. Bertaux JF Soz Praventivmed; 1980 Mar; 25(1-2):23-5. PubMed ID: 7424174 [TBL] [Abstract][Full Text] [Related]
12. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom. Cahal DA Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096 [No Abstract] [Full Text] [Related]
13. Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. Hooimeyer A; Bhasale A; Perry L; Fabbri A; Mohammad A; McEwin E; Mintzes B Pharmacol Res Perspect; 2020 Dec; 8(6):e00680. PubMed ID: 33169534 [TBL] [Abstract][Full Text] [Related]
15. Discussion on control of new drugs. Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721 [No Abstract] [Full Text] [Related]
16. Crying wolf on drug safety. Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107 [No Abstract] [Full Text] [Related]
17. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy. Simmons HE Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901 [No Abstract] [Full Text] [Related]
18. Post-marketing surveillance of new medicines. Smithells RW Br Med J; 1977 Nov; 2(6096):1218. PubMed ID: 589095 [No Abstract] [Full Text] [Related]
19. Editorial: The drug makers. Med J Aust; 1974 Oct; 2(16):583-4. PubMed ID: 4437418 [No Abstract] [Full Text] [Related]
20. AAFP supports improvement, not ban, on direct-to-consumer prescription drug ads. Kellerman R; Ann Fam Med; 2007; 5(2):180-1. PubMed ID: 17389544 [No Abstract] [Full Text] [Related] [Next] [New Search]